Novo Nordisk A/S NVO announced that CVS Health Inc’s CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.This change will take effect on July 1, 2025. “We believe in the unique benefits of Wegovy and the difference this medicine can make for patients seeking treatment,” said Dave Moore, executive vice president of U.S. Operations and president of Novo Nordisk Inc.In ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to end April, consider joining Out Fox The Street .Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in HIMS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not ...

For companies that had been undergoing fundamental challenges before the tariff volatility set in, the darkening global macroeconomy has served only to complicate matters further. And while it's understandable that investors want to shy away from risk at times likeWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. ...

Eli Lilly and Company TodayLLYEli Lilly and Company$827.87 +9.85 (+1.20%) 52-Week Range$677.09▼$972.53Dividend Yield0.72%P/E Ratio70.70Price Target$1,017.00Add to WatchlistThe world’s largest pharmaceutical stock, Eli Lilly and Company NYSE: LLY, is back in the green in 2025 as of the Apr. 21 close. Shares were down moderately in 2025 through mid-April. However, huge news came out regarding one of the company’s experimental drugs, causing shares to spike by over 14%. That drug is orforglipron, Eli Lilly’s ...

Core Insights - Ascletis Pharma Inc. announced positive topline results from its Phase Ib study of ASC30, an oral once-daily tablet for obesity treatment, demonstrating significant body weight reductions compared to placebo [3][10] - The study utilized three different weekly titration schemes, with the most effective showing a 6.5% placebo-adjusted mean body weight reduction after four weeks [4][5] Group 1: Study Design and Results - The Phase Ib study was randomized, double-blind, and placebo-controlled, conducted in the U.S. with participants having a BMI of 30-40 kg/m² [3] - Three dosing schemes were tested: - Scheme 1 (mid starting dose, slow titration) resulted in a 4.5% placebo-adjusted weight reduction - Scheme 2 (mid starting dose, normal titration) resulted in a 6.5% placebo-adjusted weight reduction - Scheme 3 (high starting dose, fast titration) resulted in a 5.0% placebo-adjusted weight reduction [4][5] - No serious adverse events were reported across all schemes, indicating a favorable safety profile [6] Group 2: Future Development Plans - Based on the Phase Ib results, the company plans to initiate a 13-week Phase IIa study with a "lower starting dose and slower titration" strategy, expected to begin in Q3 2025 [7] - The study protocol has been submitted to the U.S. FDA following preliminary consultations [7] Group 3: Product Information - ASC30 is a first and only investigational small molecule GLP-1 receptor biased agonist, designed for both oral and subcutaneous administration [8][11] - The compound has patent protection until 2044, highlighting its potential for long-term market exclusivity [11] Group 4: Company Overview - Ascletis Pharma Inc. is an innovative biotech company listed on the Hong Kong Stock Exchange, focusing on metabolic diseases and addressing unmet medical needs globally [12] - The company has multiple clinical-stage drug candidates in its pipeline, emphasizing its commitment to research and development [12]

A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg DosesChange in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of UseNo Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-WeeksAdditional Cohorts Being Added to Determine Maximum Tolerate ...

Core Insights - The article provides an overview of the investment landscape, emphasizing the importance of independent research and verification of information before making investment decisions [2][3]. Group 1 - The article highlights that past performance does not guarantee future results, indicating a need for caution among investors [3]. - It stresses that the opinions presented are based on probabilistic analysis rather than absolute certainty, which reflects the inherent volatility in stock investments [2][3]. - The content is intended for informational purposes and should not be interpreted as personalized investment advice, underscoring the necessity for investors to assess their own financial circumstances [2][3].

Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across dosesThe investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpointThe overall safety and tolerability profile of orforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies  INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Ph ...

GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with semaglutide in preclinical models--Novel mechanism of action, formulation and administration: Opaganib is a differentiated oral, non-peptide therapeutic that targets sphingosine kinase-2 (SPHK2), potentially avoiding common Glucagon-like peptide-1 (GLP-1) inhibitor side effects and administration burdens --Market ...

 Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss  Kelowna, British Columbia – April 3, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “Study”) underway in Australia.  Enrollment of patients for all 5 Study arms has now been completed on schedule. Participation interest in the Stu ...